Large-Particle Liposomal Nucleoside Delivery for Stable Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing liposomal drug delivery systems for nucleoside analogues in cancer treatment are limited by inefficiencies in delivery and stability, particularly in larger sizes, and lack effective targeting and reduced toxicity.
Innovation Solution
Development of liposomal compositions incorporating nucleoside analogues such as {[2-(6-amino-9H-purin-9-yl)quinazolin-4-yl]oxy}phosphonic acid or 2-(6-amino-9H-purin-9-yl)quinazolin-4-ol, with specific phospholipid compositions and sizes (≥800 nm) for enhanced stability and targeting, using pegylated phospholipids and sterols like cholesterol for improved incorporation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If liposomal suspensions are used for delivery of nucleoside analogues, then delivery efficiency is improved, but stability and toxicity reduction are insufficient
Solution Approach 1:
The patent modifies the physical and chemical parameters of the liposomal system by incorporating specific phospholipid compositions and adjusting particle size to ≥800 nm, which enhances stability while maintaining delivery efficiency. This parameter optimization resolves the contradiction between delivery efficiency and stability.
Solution Approach 2:
The invention uses composite liposomal structures containing multiple phospholipid types and cholesterol, creating a more stable encapsulation system for nucleoside analogues. The composite material approach improves both stability and targeted delivery, addressing the reliability concern while maintaining productivity.
2Ease of operation
If liposomal compositions are used for cancer treatment, then targeted delivery is improved, but toxicity reduction is insufficient
Solution Approach 1:
The patent applies local quality modification by functionalizing the liposome surface with specific phospholipids and cholesterol, creating targeted regions that recognize cancer cells. This localized enhancement improves targeted delivery to tumor sites while reducing systemic toxicity through selective accumulation.
Solution Approach 2:
The invention converts the potentially harmful cytotoxic nature of nucleoside analogues into a beneficial targeted therapy by encapsulating them in liposomes that selectively deliver the drug to cancer cells. The toxicity is redirected from healthy tissues to tumor cells, transforming a harmful effect into a therapeutic benefit.
3Reliability
If larger liposome sizes (≥800 nm) are used, then stability is improved, but encapsulation efficiency decreases
Solution Approach 1:
The patent optimizes the encapsulation process parameters including phospholipid composition ratios and incorporation methods to achieve high encapsulation efficiency in large-sized liposomes (≥800 nm). The specific phospholipid formulation enables stable large liposomes with improved drug loading capacity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new liposomal compositions demonstrate improved stability and targeting, with enhanced encapsulation efficiency and reduced toxicity, effectively inhibiting cancer cell proliferation in vitro at sub-micromolar concentrations.
Implementation Method 1
Liposomes encapsulate both hydrophilic and hydrophobic drugs. They are mainly composed of phospholipids, which can form single layers or bilayers in most environments. Hydrophilic drugs are usually entrapped in the interior of liposomes (aqueous environment)
Implementation Method 2
They are mainly composed of phospholipids, which can form single layers or bilayers in most environments. When phospholipids disperse at an aqueous environment at temperatures above their transition temperature they tend to form particles with an aqueous core.
Implementation Method 3
using pegylated phospholipids and sterols like cholesterol for improved incorporation efficiency
Data Source
AI summary
A pharmaceutical composition including a nucleoside analogue loaded into liposomes of a liposomal delivery system, wherein the nucleoside analogue is a purine analogue chosen from {[2-(6-amino-9H-purin-9-yl)quinazolin-4-yl]oxy}phosphonic acid or 2-(6-amino-9H-purin-9-yl) quinazolin-4-ol, or a pyrimidine analogue chosen from 4-amino-1-(4-hydroxyquinazolin-2-yl)-1,2-dihydropyrimidin-2-one or N-[1-(4-hydroxyquinazolin-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl]acetamide.